OpenPayd reported $300 billion of annualised transaction volume as of 31 July 2026, $96 million of annual recurring revenue, and 1,200 clients globally. The Nasdaq route is a merger with Titan Acquisition Corp at a pro-forma equity valuation of up to $1.145 billion, subject to shareholder approval.

I set the valuation against the revenue and get roughly twelve times ARR. For a regulated payments business with EU and US coverage I would not call that aggressive. I note that the US coverage arrived about four weeks before the quarter the listing should close in.

Each state grants its own money transmitter licence. Each one runs its own application, its own net worth and surety bond rules, and its own examination cycle. I would budget a multi-year programme across 43 separate supervisors to build that organically.

Buying the entity that already holds them turns that programme into one change of control. I compared that trade for European licences in my piece on licence premiums, where buying and building cost about the same in cash and nothing like the same in time.

OpenPayd already held a MiCA authorisation from the Malta Financial Services Authority, alongside its UK and European permissions. So I read the deal as assembling fiat and digital asset coverage across the US, UK and Europe in one regulatory stack. That stack is what the company takes to the market as a listed business.

The closest reference point I found is Polygon Labs, which committed over $250 million in January 2026 for Coinme and Sequence together. Coinme itself holds 48 state licences across the country.

I would not divide that $250 million by 48 and call it a price per licence. The consideration covered two companies, and Sequence is not a licence business. What I take from the comparison is that a near-complete US footprint traded in the hundreds of millions this year. That makes the undisclosed MSB USA price a real gap in the record rather than a detail.

Ozan Ozerk founded MSB USA, and he also founded OpenPayd. So buyer and target share a founder, and neither side disclosed the price.

I allege nothing about any of this. I do point out that a related-party acquisition at an undisclosed price, weeks before a public listing, is exactly the fact pattern a listing prospectus has to address. I would model this company off that disclosure when it lands, not off the press release now.

I take two readings from it, and they point the same way.

Hold a US state licence portfolio and I would say you hold the scarce thing. A buyer on a listing timetable or a product deadline cannot wait for applications, and I treat a portfolio covering most of the country as a different asset from a single licence. The live listings show what owners currently ask for portfolios of this kind.

On the buy side I would check what I was inheriting before the change of control. A licence carrying a supervisory history is not a clean licence. I listed the signals to look for in the revocation warning signs piece. Where no target fits, fintech licensing and incorporation is the slower route, and Fintech Builder covers the build-out that follows either path.

Neither side disclosed the MSB USA purchase price, so I can say nothing about value here. Without it I cannot compare the cost of 43 licences against the cost of applying for them, and that comparison is what would make the story useful.

I could not read the Nasdaq press release directly, because the page rate limited me. So my SPAC terms come from The Paypers and PYMNTS reporting the same announcement. I would check the ticker, the valuation and the closing quarter against the primary release before quoting any of them.

None of the coverage I read names which 43 states the licences cover. I would call 43 of fifty a substantial share, though the seven missing ones matter if they include the large states. I have not confirmed the list.

Nothing here is investment advice, and a company in the middle of a listing process is a subject where that matters. Figures here come from secondary reporting of company announcements. One primary source refused to load, the acquisition price remains undisclosed, and SPAC terms still depend on shareholder approval and customary conditions. Anyone evaluating this company or a comparable licence portfolio should read the listing disclosure when published, and take the regulatory position to counsel qualified in the relevant states.